Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells

被引:41
|
作者
Le, WD [1 ]
Rowe, DB [1 ]
Jankovic, J [1 ]
Xie, WJ [1 ]
Appel, SH [1 ]
机构
[1] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA
关键词
D O I
10.1001/archneur.56.2.194
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The pathogenesis of substantia nigra pars compacta neuronal injury in Parkinson disease (PD) remains unknown. Cerebrospinal fluid (CSF) has been reported to contain factors toxic to dopaminergic neurons. Objectives: To determine whether the cytotoxic effects of CSF of PD patients are specific for dopaminergic neurons, dependent on prior levodopa therapy, and mediated by the cytokine tumor necrosis factor alpha (TNF-alpha). Design: Specimens of CSF were evaluated in dopaminergic (MES 23.5) and nondopaminergic (N18TG2) cell lines for cytotoxicity by viability assay and by the inhibition of tyrosine hydroxylase. After specificity and time and dose response were established, CSF specimens were assayed in a blinded manner. The TNF-alpha levels in CSF were deter mined by enzyme-linked immunosorbent assay. The toxicity of TNF-alpha in MU 23.5 cells was determined. Setting: A university-based research facility. Subjects: There were 4 groups of subjects: normal control subjects (n = 10), control subjects with neurologic disease (n = 8), PD patients treated with levodopa (n = 10), and untreated subjects with PD (n = 20). Results: Specimens of CSF from 15 (50%) of 30 PD patients and 2 (11%) of 18 control subjects were cytotoxic to dopaminergic MES 23.5 cells and were nontoxic to the parental cell line N18TG2. There was no correlation between the degree of PD CSF cytotoxicity, levodopa therapy, or the severity and duration of PD. Terminal deoxynucleotidyl transferase-mediated biotin-deoxyuridine triphosphate nick-end labeling (TUNEL) for DNA fragmentation suggested the involvement of apoptotic mechanisms. The inhibition of tyrosine hydroxylase was an early effect of cell injury by PD CSF and correlated with the viability assay. The mean TNF-alpha level was 2.6-fold higher in CSF specimens from PD patients than in those of controls. The addition of recombinant human TNF-alpha equivalent to the highest level determined in PD CSF was not cytotoxic to MES 23.5 cultures. Conclusions: Blinded CSF specimens from PD patients, regardless of therapy, contain factors that cause specific dopaminergic neuronal cell injury. These factors are present in a substantial proportion of CSF specimens from patients with early PD, before the institution of medical therapy. Levels of TNF-alpha are elevated in the CSF of PD patients, but TNF-alpha is not responsible for the cytotoxicity.
引用
收藏
页码:194 / 200
页数:7
相关论文
共 50 条
  • [1] Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson's disease
    Ishibashi, K.
    Kanemaru, K.
    Saito, Y.
    Murayama, S.
    Oda, K.
    Ishiwata, K.
    Mizusawa, H.
    Ishii, K.
    ACTA NEUROLOGICA SCANDINAVICA, 2010, 122 (01): : 46 - 51
  • [2] Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease
    Boll, MC
    Sotelo, J
    Otero, E
    Alcaraz-Zubeldia, M
    Rios, C
    NEUROSCIENCE LETTERS, 1999, 265 (03) : 155 - 158
  • [3] Cerebrospinal fluid levels of thiamine in patients with Parkinson's disease
    Jiménez-Jiménez, FJ
    Molina, JA
    Hernánz, A
    Fernández-Vivancos, E
    de Bustos, F
    Barcenilla, B
    Gómez-Escalonilla, C
    Zurdo, M
    Berbel, A
    Villanueva, C
    NEUROSCIENCE LETTERS, 1999, 271 (01) : 33 - 36
  • [4] Proteomic analysis of the cerebrospinal fluid of Parkinson's disease patients
    Guo, Jiguang
    Sun, Zhongwu
    Xiao, Shifu
    Liu, Dong-ping
    Jin, Guohua
    Wang, Ersong
    Zhou, Jiangning
    Zhou, Jiawei
    CELL RESEARCH, 2009, 19 (12) : 1401 - 1403
  • [5] Proteomic analysis of the cerebrospinal fluid of Parkinson's disease patients
    Jiguang Guo
    Zhongwu Sun
    Shifu Xiao
    Dongping Liu
    Guohua Jin
    Ersong Wang
    Jiangning Zhou
    Jiawei Zhou
    Cell Research, 2009, 19 : 1401 - 1403
  • [6] Cerebrospinal fluid nitrate levels in patients with Parkinson's disease
    Molina, JA
    JimenezJimenez, FJ
    Navarro, JA
    Vargas, C
    Gomez, P
    BenitoLeon, J
    OrtiPareja, M
    Cisneros, E
    Arenas, J
    ACTA NEUROLOGICA SCANDINAVICA, 1996, 93 (2-3): : 123 - 126
  • [7] Cerebrospinal fluid carnitine levels in patients with Parkinson's disease
    JimenezJimenez, FJ
    Rubio, JC
    Molina, JA
    Martin, MA
    Campos, Y
    BenitoLeon, J
    OrtiPareja, M
    Gasalla, T
    Arenas, J
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 1997, 145 (02) : 183 - 185
  • [8] Elemental profile of cerebrospinal fluid in patients with Parkinson's disease
    Alimonti, Alessandro
    Bocca, Beatrice
    Pino, Anna
    Ruggieri, Flavia
    Forte, Giovanni
    Sancesario, Giuseppe
    JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY, 2007, 21 (04) : 234 - 241
  • [9] Cerebrospinal fluid biomarkers in Parkinson disease
    Lucilla Parnetti
    Anna Castrioto
    Davide Chiasserini
    Emanuele Persichetti
    Nicola Tambasco
    Omar El-Agnaf
    Paolo Calabresi
    Nature Reviews Neurology, 2013, 9 : 131 - 140
  • [10] Cerebrospinal fluid biomarkers in Parkinson disease
    Parnetti, Lucilla
    Castrioto, Anna
    Chiasserini, Davide
    Persichetti, Emanuele
    Tambasco, Nicola
    El-Agnaf, Omar
    Calabresi, Paolo
    NATURE REVIEWS NEUROLOGY, 2013, 9 (03) : 131 - 140